About Caris Life Sciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.carislifesciences.com/
Frequently Asked Questions
What is the 52-week range for CAI?
The 52-week high is $33.655 and the 52-week low is $14.19.
What is the P/E ratio for CAI?
The Price to Earnings (P/E) ratio is 76.20.
What is the dividend yield for CAI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 18.77%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 10.62%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 13.19.
Analyst Recommendation Trends
Wall Street analyst consensus for CAI over the last few months:
Latest CAI News
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure
Caris Life Sciences® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy. By integrating Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and whole-blood analysis (for true CHIP identification) into a single platform, the enhanced Caris Assure assay provides a more complete molecular profile from a single blood draw, delivering deeper insights to help guide precision oncology decisions.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
In general, many current shareholders have lived through a deep correction that started after Caris Life Sciences peaked at 42.50 on Aug. 22 last year. Thus, Caris Life Sciences is still extended. Caris Life Sciences uses artificial intelligence and other technology to profile molecules of interest to the life sciences industry.
Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)
Caris Life Sciences' Q2 featured accelerating clinical volumes, 68% gross margin, and strong early traction for Caris Detect. Read why CAI stock is a Hold.
Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.
Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.
Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.
Caris Life Sciences: Diagnostics Growth With Room To Run
Bullish take on CAI stock: profiling revenue funds diagnostics growth as molecular data powers new tests.
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems. “Samantha brings more than two de
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner. The partnership is designed to raise awareness of the critical importance of early cancer detection and introduce a national audience to Caris Detect™, Caris' groundbreaking multi-cancer early detection (MCED) blood test.
Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?
Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presentations and August’s pancreatic cancer AI publication land against a mixed share price backdrop for Caris Life Sciences, with the stock down 28.06% on a 1 year total shareholder return basis but showing strong 90 day share price momentum of 55.33% and a 30 day...
Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference
Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Denton John Russel | -7,500 | $31.8168 | $238,626 |
| 2026-09-17 | Brille Brian J | -400,000 | - | - |
| 2026-09-17 | Brille Brian J | -400,000 | $30.3302 | $12,132,080 |
| 2026-09-17 | Brille Brian J | +400,000 | $2.44 | $976,000 |
| 2026-09-04 | Spetzler David Baxley | -250,000 | - | - |
| 2026-09-04 | Spetzler David Baxley | -119,212 | $24.7552 | $2,951,117 |
| 2026-09-04 | Spetzler David Baxley | +250,000 | $2.44 | $610,000 |
| 2026-09-03 | Spetzler David Baxley | -1,000,000 | - | - |
| 2026-09-03 | Spetzler David Baxley | -84,900 | $25.3201 | $2,149,676 |
| 2026-09-03 | Spetzler David Baxley | -393,100 | $24.7604 | $9,733,313 |
| 2026-09-03 | Spetzler David Baxley | +1,000,000 | $2.44 | $2,440,000 |
| 2026-08-14 | Fredrickson David Paul | +13,192 | - | - |
| 2026-08-14 | Minor Lloyd | +13,192 | - | - |
| 2026-08-14 | Vacirca Jeff L | +13,192 | - | - |
| 2026-08-14 | Gilliam Joseph E | +13,192 | - | - |
| 2026-08-14 | PHILLIPS T DANNY | +13,192 | - | - |
| 2026-08-14 | CASTLEMAN PETER M | +13,192 | - | - |
| 2026-08-14 | JOHANSEN LAURA I | +13,192 | - | - |
| 2026-08-14 | HALBERT JON | +13,192 | - | - |
| 2026-05-29 | Knowles Jonathan Kenneth Charles | +1,600 | $15.62 | $24,992 |
| 2026-05-29 | POSTE GEORGE | +1,600 | $15.62 | $24,992 |
| 2026-05-15 | HALBERT JON | +68,000 | $14.56 | $990,080 |
| 2026-05-15 | Power Luke Thomas | -9,771 | $15.25 | $149,008 |
| 2026-05-15 | Brille Brian J | -13,987 | $15.25 | $213,302 |
| 2026-05-15 | Spetzler David Baxley | -13,856 | $15.25 | $211,304 |
| 2026-05-15 | Denton John Russel | -6,047 | $15.25 | $92,217 |
| 2026-05-15 | HALBERT DAVID D | -40,712 | $15.25 | $620,858 |
| 2026-05-11 | Vacirca Jeff L | +31,050 | $16.149 | $501,426 |
| 2026-03-06 | Power Luke Thomas | +63,971 | - | - |
| 2026-03-06 | Brille Brian J | +83,162 | - | - |
| 2026-03-06 | Spetzler David Baxley | +83,162 | - | - |
| 2026-03-06 | Denton John Russel | +63,971 | - | - |
| 2026-03-06 | HALBERT DAVID D | +320,112 | - | - |
| 2026-02-26 | Minor Lloyd | +2,492 | $20.06 | $49,990 |
| 2026-02-26 | Fredrickson David Paul | +2,492 | $20.06 | $49,990 |
| 2026-02-26 | Vacirca Jeff L | +2,492 | $20.06 | $49,990 |
| 2026-02-26 | PHILLIPS T DANNY | +3,739 | $20.06 | $75,004 |
| 2026-02-26 | CASTLEMAN PETER M | +5,509 | $20.06 | $110,511 |
| 2026-02-26 | HALBERT JON | +2,492 | $20.06 | $49,990 |
| 2026-01-09 | CASTLEMAN PETER M | -2,500 | - | - |
| 2026-01-09 | CASTLEMAN PETER M | +2,500 | $18.6 | $46,500 |
| 2025-12-11 | Power Luke Thomas | -37,500 | - | - |
| 2025-12-11 | Power Luke Thomas | -24,750 | - | - |
| 2025-12-11 | Power Luke Thomas | -1,400 | $27.1554 | $38,018 |
| 2025-12-11 | Power Luke Thomas | -60,850 | $26.5644 | $1,616,444 |
| 2025-12-11 | Power Luke Thomas | +37,500 | $2.44 | $91,500 |
| 2025-12-11 | Power Luke Thomas | +24,750 | $2.44 | $60,390 |
| 2025-12-11 | Brille Brian J | -650 | - | - |
| 2025-12-10 | Brille Brian J | -650 | - | - |
| 2025-11-07 | Spetzler David Baxley | +400 | $23.85 | $9,540 |
| 2025-11-07 | Denton John Russel | +4,184 | $24.09 | $100,793 |